Catherine T. Doherty insider trades: Quest Diagnostics (DGX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Catherine reports to the SEC
Open-market buys and sales
40 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 3, 2026 | DGX | ↓ Sell | 22,105 | $248.02 | $5.5M | Direct | Nov 5, 2026 (2d) |
| Mar 5, 2026 | DGX | ↓ Sell | 5,558 | $206.21 | $1.1M | Direct | Mar 6, 2026 (1d) |
| Mar 3, 2026 | DGX | ↓ Sell | 632 | $207.73 | $131K | Direct | Mar 4, 2026 (1d) |
| Feb 19, 2026 | DGX | ↓ Sell10b5-1 | 1,433 | $204.83 | $294K | Direct | Feb 20, 2026 (1d) |
| Feb 13, 2026 | DGX | ↓ Sell | 26,165 | $206.15 | $5.4M | Direct | Feb 17, 2026 (4d) |
| Mar 5, 2025 | DGX | ↓ Sell | 5,370 | $174.13 | $935K | Direct | Mar 7, 2025 (2d) |
| Mar 4, 2025 | DGX | ↓ Sell | 716 | $175.79 | $126K | Direct | Mar 5, 2025 (1d) |
| Feb 27, 2025 | DGX | ↓ Sell | 824 | $172.61 | $142K | Direct | Feb 28, 2025 (1d) |
| Feb 20, 2025 | DGX | ↓ Sell | 1,434 | $170.51 | $245K | Direct | Feb 21, 2025 (1d) |
| Nov 27, 2024 | DGX | ↓ Sell | 33,103 | $162.99 | $5.4M | Direct | Dec 2, 2024 (5d) |
| Feb 29, 2024 | DGX | ↓ Sell | 6,744 | $126.45 | $853K | Direct | Mar 1, 2024 (1d) |
| Feb 22, 2024 | DGX | ↓ Sell | 821 | $126.14 | $104K | Direct | Feb 23, 2024 (1d) |
| Mar 7, 2023 | DGX | ↓ Sell | 5,307 | $140.55 | $746K | Direct | Mar 8, 2023 (1d) |
| Mar 3, 2023 | DGX | ↓ Sell | 717 | $140.63 | $101K | Direct | Mar 6, 2023 (3d) |
| Feb 24, 2023 | DGX | ↓ Sell | 1,690 | $141.42 | $239K | Direct | Feb 27, 2023 (3d) |
| Nov 28, 2022 | DGX | ↓ Sell | 40,765 | $149.18 | $6.1M | Direct | Nov 29, 2022 (1d) |
| Mar 8, 2022 | DGX | ↓ Sell | 7,032 | $135.21 | $951K | Direct | Mar 9, 2022 (1d) |
| Feb 24, 2022 | DGX | ↓ Sell | 2,750 | $126.26 | $347K | Direct | Feb 28, 2022 (4d) |
| Nov 29, 2021 | DGX | ↓ Sell | 37,565 | $156.81 | $5.9M | Direct | Dec 1, 2021 (2d) |
| May 7, 2021 | DGX | ↓ Sell | 8,536 | $139.96 | $1.2M | Direct | May 11, 2021 (4d) |
| Sep 2, 2020 | DGX | ↓ Sell | 58,392 | $110.60 | $6.5M | Direct | Sep 4, 2020 (2d) |
| Mar 11, 2020 | DGX | ↓ Sell | 2,501 | $104.25 | $261K | Direct | Mar 12, 2020 (1d) |
| Feb 27, 2020 | DGX | ↓ Sell | 1,157 | $109.68 | $127K | Direct | Feb 28, 2020 (1d) |
| Feb 25, 2020 | DGX | ↓ Sell10b5-1 | 405 | $112.73 | $46K | Direct | Feb 26, 2020 (1d) |
| Apr 4, 2019 | DGX | ↓ Sell | 66,382 | $90.59 | $6.0M | Direct | Apr 8, 2019 (4d) |
| Mar 5, 2018 | DGX | ↓ Sell | 5,556 | $101.00 | $561K | Direct | Mar 6, 2018 (1d) |
| Feb 28, 2018 | DGX | ↓ Sell | 1,820 | $104.38 | $190K | Direct | Mar 1, 2018 (1d) |
| Feb 26, 2018 | DGX | ↓ Sell10b5-1 | 397 | $102.74 | $41K | Direct | Feb 27, 2018 (1d) |
| Jan 24, 2018 | DGX | ↓ Sell | 21,294 | $104.00 | $2.2M | Direct | Jan 26, 2018 (2d) |
| Jun 19, 2017 | DGX | ↓ Sell | 59,762 | $107.55 | $6.4M | Direct | Jun 21, 2017 (2d) |
| Mar 3, 2017 | DGX | ↓ Sell | 7,162 | $98.28 | $704K | Direct | Mar 6, 2017 (3d) |
| Feb 15, 2017 | DGX | ↓ Sell | 1,615 | $94.65 | $153K | Direct | Feb 17, 2017 (2d) |
| Jan 30, 2017 | DGX | ↓ Sell | 80,000 | $90.58 | $7.2M | Direct | Feb 1, 2017 (2d) |
| May 27, 2016 | DGX | ↓ Sell | 47,334 | $77.27 | $3.7M | Direct | Jun 1, 2016 (5d) |
| Apr 25, 2016 | DGX | ↓ Sell | 29,550 | $74.45 | $2.2M | Direct | Apr 27, 2016 (2d) |
| Nov 3, 2014 | DGX | ↓ Sell | 23,667 | $62.19 | $1.5M | Direct | Nov 5, 2014 (2d) |
| Aug 8, 2014 | DGX | ↓ Sell | 25,000 | $60.12 | $1.5M | Direct | Aug 11, 2014 (3d) |
| Sep 17, 2013 | DGX | ↓ Sell | 43,334 | $62.00 | $2.7M | Direct | Sep 18, 2013 (1d) |
| Aug 14, 2013 | DGX | ↓ Sell | 33,000 | $59.85 | $2.0M | Direct | Aug 15, 2013 (1d) |
| Aug 8, 2012 | DGX | ↓ Sell | 40,000 | $60.11 | $2.4M | Direct | Aug 9, 2012 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other DGX insiders
Open-market trades in the last 12 months
About Catherine T. Doherty's insider trades
Catherine T. Doherty is Executive Vice President at Quest Diagnostics (DGX). Since Aug 8, 2012, Catherine has reported no open-market purchases and 40 sales worth $82.1M on SEC Form 4. In the last 12 months: 5 sales ($12.4M).
3 sales (0% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include shares withheld for taxes (47 filings), grants and awards (30 filings), option exercises (17 filings), gifts (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every DGX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.